GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Change in the hepatic profile of hepatitis C virus genotype 4–infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE‐II study
    Wiley ; 2018
    In:  Journal of Medical Virology Vol. 90, No. 11 ( 2018-11), p. 1739-1744
    Details
    In: Journal of Medical Virology, Wiley, Vol. 90, No. 11 ( 2018-11), p. 1739-1744
    Abstract: In AGATE‐II, treatment with ombitasvir coformulated with paritaprevir/ritonavir plus ribavirin (RBV) in Egyptians infected with hepatitis C virus genotype 4 resulted in high rates of sustained virologic response at post‐treatment week 12. This subanalysis examined the effects of treatment in AGATE‐II on liver biomarkers in patients with compensated cirrhosis. AGATE‐II was a phase 3, open‐label, partly randomized trial of ombitasvir/paritaprevir/ritonavir with weight‐based RBV daily once in treatment‐naive or treatment‐experienced patients. Patients without cirrhosis received treatment for 12 weeks and patients with compensated cirrhosis were randomized 1:1 to the same regimen for either 12 or 24 weeks. Sixty patients with compensated cirrhosis were randomized to treatment for 12 weeks (n = 31) or 24 weeks (n = 29). In the 12‐week arm, significant improvements were observed in biomarkers of liver injury (alanine aminotransferase: –53.7 U/L, P   〈  0.001; aspartate aminotransferase: –35.9 U/L, P   〈  0.001) and liver fibrosis (aspartate aminotransferase to platelet ratio index: –0.987, P   〈  0.001; fibrosis‐4 index: –1.165, P   〈  0.001). Similar results were reported in the 24‐week arm. Treatment with ombitasvir/paritaprevir/ritonavir plus RBV in hepatitis C virus genotype, 4‐infected Egyptians with compensated cirrhosis resulted in improvements in certain biomarkers of liver synthetic function, injury, and fibrosis, independent of treatment duration.
    Type of Medium: Online Resource
    ISSN: 0146-6615 , 1096-9071
    URL: Issue
    URL: Article
    DOI: 10.1002/jmv.v90.11
    DOI: 10.1002/jmv.25243
    RVK:
    XA 10000
    Language: English
    Publisher: Wiley
    Publication Date: 2018
    detail.hit.zdb_id: 752392-0
    detail.hit.zdb_id: 1475090-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    MAFLD predicts cardiovascular disease risk better than MASLD
    Wiley ; 2024
    In:  Liver International Vol. 44, No. 7 ( 2024-07), p. 1567-1574
    Details
    In: Liver International, Wiley, Vol. 44, No. 7 ( 2024-07), p. 1567-1574
    Abstract: Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic dysfunction‐associated fatty liver disease (MAFLD). We compared the abilities of MAFLD and MASLD to predict the risk of atherosclerotic cardiovascular disease (ASCVD). Methods Six thousand and ninety six participants from the 2017 to 2020 National Health and Nutrition Examination Survey cohort who received a thorough medical health check‐up were chosen for the study. The associations between fatty liver status and coronary risk surrogates, such as 10‐year ASCVD risk and self‐reported cardiovascular events, were analysed. Results MAFLD and MASLD were identified in 2911 (47.7%) and 2758 (45.2%) patients, respectively. MAFLD (odds ratio [OR]: 2.14, 95% confidence interval [CI] , 1.78–2.57, p 〈 .001) was more strongly independently associated with high ASCVD risk than MASLD (OR: 1.82, 95% CI, 1.52–2.18, p 〈 .001) was in comparison with the absence of each condition. However, compared with MAFLD, MASLD alone was not associated with increased ASCVD risk. Multiple logistic regression revealed that MAFLD alone was significantly more strongly associated with a high risk of ASCVD (OR: 2.82; 95% CI: 1.13–7.01; p 〈 .03) than MASLD alone. Conclusions Although both MAFLD and MASLD were associated with different ASCVD risks, MAFLD predicted the ASCVD risk better than MASLD. The higher predictive ability of MAFLD compared to MASLD was attributed to metabolic dysfunction rather than moderate alcohol use.
    Type of Medium: Online Resource
    ISSN: 1478-3223 , 1478-3231
    URL: Issue
    URL: Article
    DOI: 10.1111/liv.v44.7
    DOI: 10.1111/liv.15931
    Language: English
    Publisher: Wiley
    Publication Date: 2024
    detail.hit.zdb_id: 2124684-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression : Nilotinib counteracts hepatic oxidative stress
    Wiley ; 2011
    In:  Fundamental & Clinical Pharmacology Vol. 25, No. 2 ( 2011-04), p. 248-257
    Details
    In: Fundamental & Clinical Pharmacology, Wiley, Vol. 25, No. 2 ( 2011-04), p. 248-257
    Type of Medium: Online Resource
    ISSN: 0767-3981
    URL: Issue
    URL: Article
    DOI: 10.1111/fcp.2011.25.issue-2
    DOI: 10.1111/j.1472-8206.2010.00824.x
    Language: English
    Publisher: Wiley
    Publication Date: 2011
    detail.hit.zdb_id: 2006242-4
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Letter: comparison of clinical prediction rules for ruling out cirrhosis in non‐alcoholic fatty liver disease ( NAFLD )
    Wiley ; 2022
    In:  Alimentary Pharmacology & Therapeutics Vol. 56, No. 6 ( 2022-09), p. 1098-1099
    Details
    In: Alimentary Pharmacology & Therapeutics, Wiley, Vol. 56, No. 6 ( 2022-09), p. 1098-1099
    Abstract: LINKED CONTENT This article is linked to Brandman et al papers. To view these articles, visit https://doi.org/10.1111/apt.16874
    Type of Medium: Online Resource
    ISSN: 0269-2813 , 1365-2036
    URL: Issue
    URL: Article
    DOI: 10.1111/apt.v56.6
    DOI: 10.1111/apt.17174
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2003094-0
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Seroprevalence and epidemiological characteristics of HDV infection among HBV patients in the Nile Delta, Egypt
    Wiley ; 2022
    In:  Journal of Viral Hepatitis Vol. 29, No. 1 ( 2022-01), p. 87-90
    Details
    In: Journal of Viral Hepatitis, Wiley, Vol. 29, No. 1 ( 2022-01), p. 87-90
    Abstract: The epidemiology of HDV infection worldwide is obscure. Mapping the epidemiology of the infection is highly required, so, we aimed to estimate the prevalence of hepatitis D virus infection among chronic hepatitis B patients and the epidemiological characteristics in the Nile delta in Egypt. This was a prospective observational cross‐sectional study including consecutive chronic hepatitis B patients in the out‐patient clinics at the Egyptian Liver Research Institute and Hospital (ELRIAH) and its satellites in the Nile Delta from January 2016 until August 2018. They were recruited from patients enrolled in Educate, Test and Treat program, which was implemented in 73 Egyptian Villages. Subjects were tested by using HBsAg serological rapid diagnostic tests (RDTs), and then HBV DNA by PCR was done in HBsAg‐positive cases. HDV IgG antibody testing and confirmatory HDV RNA PCR were done. Complete liver functions, abdominal ultrasonography and FibroScan were also performed. The prevalence of HDV was 3.4% using anti‐delta antibody (22/631), and only 8 were positive for HDV RNA (8/22, 36.4%). Overall HDV prevalence using PCR was 8/631(1.27%). HDV‐positive cases were mainly males (68.2%). Eight cases were cirrhotic (36.4%), 3 (13.6%) had HCC and 7 (31.8%) were HBeAg positive. HDV prevalence is low among chronic hepatitis B patients in the Nile delta, Egypt. Screening for HDV IgG is recommended in CHB patients who had cirrhosis, HCC or HBeAg positive.
    Type of Medium: Online Resource
    ISSN: 1352-0504 , 1365-2893
    URL: Issue
    URL: Article
    DOI: 10.1111/jvh.v29.1
    DOI: 10.1111/jvh.13621
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2007924-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients
    Wiley ; 2022
    In:  Journal of Viral Hepatitis Vol. 29, No. 9 ( 2022-09), p. 807-816
    Details
    In: Journal of Viral Hepatitis, Wiley, Vol. 29, No. 9 ( 2022-09), p. 807-816
    Abstract: We have recently demonstrated the ability of a simple predictive model (GES) score to determine the risk of hepatocellular carcinoma (HCC) after using direct‐acting antivirals. However, our results were restricted to Egyptian patients with hepatitis C virus (HCV) genotype 4. Therefore, we studied a large, independent cohort of multiethnic populations through our international collaborative activity. Depending on their GES scores, patients are stratified into low risk (≤ 6/12.5), intermediate risk ( 〉  6–7.5/12.5), and high risk ( 〉  7.5/12.5) for HCC. A total of 12,038 patients with chronic HCV were analyzed in this study, of whom 11,202 were recruited from 54 centers in France, Japan, India, the U.S., and Spain, and the remaining 836 were selected from the Gilead‐sponsored randomized controlled trial conducted across the U.S., Europe, Canada, and Australia. Descriptive statistics and log‐rank tests. The performance of the GES score was evaluated using Harrell's C‐index (HCI). The GES score proved successful at stratifying all patients into 3 risk groups, namely low‐risk, intermediate‐risk, and high‐risk. It also displayed significant predictive value for HCC development in all participants ( p   〈  .0001), with HCI ranging from 0.55 to 0.76 among all cohorts after adjusting for HCV genotypes and patient ethnicities. The GES score can be used to stratify HCV patients into 3 categories of risk for HCC, namely low‐risk, intermediate‐risk, and high‐risk, irrespective of their ethnicities or HCV genotypes. This international multicenter validation may allow the use of GES score in individualized HCC risk‐based surveillance programs.
    Type of Medium: Online Resource
    ISSN: 1352-0504 , 1365-2893
    URL: Issue
    URL: Article
    DOI: 10.1111/jvh.v29.9
    DOI: 10.1111/jvh.13717
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2007924-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    GES: A validated simple score to predict the risk of HCC in patients with HCV‐GT4‐associated advanced liver fibrosis after oral antivirals
    Wiley ; 2020
    In:  Liver International Vol. 40, No. 11 ( 2020-11), p. 2828-2833
    Details
    In: Liver International, Wiley, Vol. 40, No. 11 ( 2020-11), p. 2828-2833
    Abstract: Hepatocellular carcinoma (HCC) risk persists after hepatitis C virus (HCV) eradication with direct‐acting antivirals (DAAs), particularly in patients with cirrhosis. Identifying those who are likely to develop HCC is a critical unmet medical need. Our aim is to develop a score that offers individualized patient HCC risk prediction. Methods This two‐centre prospective study included 4400 patients, with cirrhosis and advanced fibrosis who achieved a sustained virologic response (SVR), including 2372 patients (derivation cohort). HCC‐associated factors were identified by multivariable Cox regression analysis to develop a scoring model for prediction of HCC risk; and subsequently internally and externally validated in two independent cohorts of 687 and 1341 patients. Results In the derivation cohort, the median follow‐up was 23.51 ± 8.21 months, during which 109 patients (4.7%) developed HCC. Age, sex, serum albumin, α fetoprotein and pretreatment fibrosis stage were identified as risk factors for HCC. A simple predictive model (GES) score was constructed. The 2‐year cumulative HCC incidence using Kaplan‐Meier method was 1.2%, 3.3% and 7.1% in the low‐risk, medium‐risk and high‐risk groups respectively. Internal and external validation showed highly significant difference among the three risk groups ( P   〈  .001) with regard to cumulative HCC risk. GES score has high predictive ability value (Harrell's C statistic 0.801), that remained robustly consistent across two independent validation cohorts (Harrell's C statistic 0.812 and 0.816). Conclusion GES score is simple with validated good predictive ability for the development of HCC after eradication of HCV and may be useful for HCC risk stratification in those patients.
    Type of Medium: Online Resource
    ISSN: 1478-3223 , 1478-3231
    URL: Issue
    URL: Article
    DOI: 10.1111/liv.v40.11
    DOI: 10.1111/liv.14666
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2124684-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Development of a simple dynamic algorithm for individualized hepatocellular carcinoma risk‐based surveillance using pre‐ and post‐treatment general evaluation score
    Wiley ; 2021
    In:  Liver International Vol. 41, No. 11 ( 2021-11), p. 2768-2776
    Details
    In: Liver International, Wiley, Vol. 41, No. 11 ( 2021-11), p. 2768-2776
    Abstract: With the growing number of treated hepatitis C patients, the current ‘one‐size‐fits‐all’ hepatocellular carcinoma (HCC) surveillance strategies for patients with advanced fibrosis represents a great burden on healthcare systems. An individualized HCC risk strategy incorporates the dynamic changes of HCC risk are lacking. Methods This single‐centre observational study included 3075 patients, with advanced fibrosis (≥F3) who achieved SVR following DAAs at Egyptian Liver research institute and hospital (ELRIAH) with follow‐up period (range 6‐72 months). The performance of a recently developed General Evaluation Score (GES) HCC risk stratification score was calculated pre‐ and post‐treatment using Harrell’s c statistic. Times to HCC and cumulative incidences were calculated with Kaplan–Meier method and compared using log‐rank (Mantel‐Cox) test. Results Pre‐treatment GES score stratified patients into low (60.4%), intermediate (23.4%), and (16.2%) high‐risk score where 5‐year cumulative incidences of HCC were 1.66%, 4.45% and 7.64%, respectively. Harrell’s c statistic was 0.801. Post‐treatment GES score stratified patients into low (57.4%), intermediate (30.7%) and (11.9%) high‐risk score where 5‐year cumulative incidences of HCC were 1.35%, 3.49% and 11.09% respectively. The cumulative HCC incidence increased significantly with higher scores ( P 〈 .001). Harrell's c statistic was 0.818. Using pre‐ and post‐treatment GES score, GES algorithm was developed with higher predictive value. The cumulative HCC incidence increased significantly with higher scores ( P 〈 .001). Harrell’s c statistic was 0.832. Conclusion A dynamic algorithm incorporating both pre‐ and post‐GES scores have better performance and predictive value compared with only pre‐treatment assessments. The proposed algorithm would help to stratify those who need intensive or being excluded from screening.
    Type of Medium: Online Resource
    ISSN: 1478-3223 , 1478-3231
    URL: Issue
    URL: Article
    DOI: 10.1111/liv.v41.11
    DOI: 10.1111/liv.14995
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2124684-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Systemic inflammatory response syndrome in acute‐on‐chronic liver failure: Relevance of ‘golden window’: A prospective study
    Wiley ; 2017
    In:  Journal of Gastroenterology and Hepatology Vol. 32, No. 12 ( 2017-12), p. 1989-1997
    Details
    In: Journal of Gastroenterology and Hepatology, Wiley, Vol. 32, No. 12 ( 2017-12), p. 1989-1997
    Abstract: Systemic inflammatory response syndrome (SIRS) is an early marker of sepsis and ongoing inflammation and has been reported in large proportion of acute‐on‐chronic liver failure (ACLF) patients. Whether sepsis is the cause or the result of liver failure is unclear and is vital to know. To address this, the study investigated the course and outcome of ACLF patients without SIRS/sepsis. Methods Consecutive ACLF patients were monitored for the development of SIRS/sepsis and associated complications and followed till 90 days, liver transplant or death. Results Of 561 patients, 201 (35.8%) had no SIRS and 360 (64.2%) had SIRS with or without infection. New onset SIRS and sepsis developed in 74.6% and 8% respectively in a median of 7 (range 4–15) days, at a rate of 11% per day. The cumulative incidence of new SIRS was 29%, 92.8%, and 100% by days 4, 7, and 15. Liver failure, that is, bilirubin 〉  12 mg/dL (odds ratio [OR] = 2.5 [95% confidence interval {CI} = 1.05–6.19] , P  = 0.04) at days 0 and 4, and renal failure at day 4 (OR = 6.74 [95%CI = 1.50–13.29], P  = 0.01), independently predicted new onset SIRS. Absence of SIRS in the first week was associated with reduced incidence of organ failure (20% vs 39.4%, P  = 0.003), as was the 28‐day (17.6% vs 36%, P  = 0.02) and 90‐day (27.5% vs 51%, P  = 0.002) mortality. The 90‐day mortality was 61.6% in the total cohort and that for those having no SIRS and SIRS at presentation were 42.8% and 65%, respectively ( P   〈  0.001). Conclusion Liver failure predicts the development of SIRS. New onset SIRS in the first week is an important determinant of early sepsis, organ failure, and survival. Prompt interventions in this ‘golden window’ before development of sepsis may improve the outcome of ACLF.
    Type of Medium: Online Resource
    ISSN: 0815-9319 , 1440-1746
    URL: Issue
    URL: Article
    DOI: 10.1111/jgh.2017.32.issue-12
    DOI: 10.1111/jgh.13799
    Language: English
    Publisher: Wiley
    Publication Date: 2017
    detail.hit.zdb_id: 2006782-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    A same day ‘test and treat’ model for chronic HCV and HBV infection: Results from two community‐based pilot studies in Egypt
    Wiley ; 2020
    In:  Journal of Viral Hepatitis Vol. 27, No. 6 ( 2020-06), p. 593-601
    Details
    In: Journal of Viral Hepatitis, Wiley, Vol. 27, No. 6 ( 2020-06), p. 593-601
    Abstract: Prompt access to confirmatory viral load testing and staging of liver disease are key barriers in uptake of treatment for chronic hepatitis B and C infection. Our objective was to establish the feasibility of a same day ‘test and treat’ model in two distinct community‐based settings in Egypt through use of key point‐of‐care (POC) portable tools for HCV and HBV viral load assessment and staging of liver disease followed by treatment initiation. Community sites were a village in northern Egypt (site 1) and a government office in Cairo (site 2). The following model was adopted: community awareness raising in the week before project initiation; site assessment to ensure optimal placement and calibration of equipment and clinical care set‐up; transfer of key portable laboratory instruments to the sites (four cartridge GeneXpert, FibroScan and abdominal ultrasound); screening using rapid diagnostic tests for HCV‐Ab and HBsAg, with immediate venous or finger‐stick blood sampling for HCV‐RNA and HBV‐DNA assay, FibroScan staging of liver disease and ultrasound screening for liver cancer. At site 1, 475 individuals were screened over a single day, 125 were positive for HCV‐Ab and 4 for HBsAg, 43 of 56 new HCV diagnoses were HCV RNA positive, and 3 of 4 HBsAg positive were HBV DNA positive, 40 initiated HCV treatment, and one HBV treatment . At site 2, 3188 individuals were screened over 3 days, 157 were positive for HCV‐Ab, and 27 for HBsAg; 38 of 76 new HCV diagnoses were HCV RNA positive, and 15 of 18 HBsAg positive were HBV‐DNA positive. Across both sites, 78 patients were counselled and initiated on treatment for HCV and 12 for HBV within 3 and 4 hours, respectively, of initial positive rapid diagnostic test result. We have shown the feasibility of a same day ‘test and treat’ model for chronic HCV and HBV infection in two community‐based settings in Egypt that achieved high levels of linkage to care and initial treatment.
    Type of Medium: Online Resource
    ISSN: 1352-0504 , 1365-2893
    URL: Issue
    URL: Article
    DOI: 10.1111/jvh.v27.6
    DOI: 10.1111/jvh.13268
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2007924-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...